Last $46.69 USD
Change Today +0.06 / 0.13%
Volume 915.3K
CTRX On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ GS
Berlin
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

catamaran corp (CTRX) Key Developments

Catamaran Seeks Acquisitions

Catamaran Corporation (TSX:CCT) is seeking acquisitions. Mike Shapiro, Chief Financial Officer of Catamaran, said, "We have a tremendous balance sheet, we have financial capacity and we have the human capacity today to integrate additional opportunities." Shapiro added, "We're going to generate roughly $500 million of cash this year. We're in a fortunate position to have significant amount of capital to deploy, we still think the most valuable opportunity is through M&A."

Catamaran Corporation Presents at CIBC 13th Annual Eastern Institutional Investor Conference, Sep-18-2014 10:00 AM

Catamaran Corporation Presents at CIBC 13th Annual Eastern Institutional Investor Conference, Sep-18-2014 10:00 AM. Venue: Le Centre Sheraton Montreal Hotel, 1201 Rene-Levesque Blvd, Montreal, Quebec, Canada. Speakers: Tony Perkins, Investor Relations.

Catamaran Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 02:55 PM

Catamaran Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 02:55 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Jeffrey G. Park, Executive Vice President of Operations, Michael H. Shapiro, Chief Financial Officer and Senior Vice President.

Catamaran Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for Full Year 2014

Catamaran Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $5,385,808,000 against $3,417,430,000 a year ago. Operating income was $135,108,000 against $106,671,000 a year ago. Income before income taxes was $119,482,000 against $95,764,000 a year ago. Net income attributable to the company was $71,432,000 or $0.34 per diluted share against $63,421,000 or $0.31 per diluted share a year ago. Net cash provided by operating activities was $57,206,000 against $172,983,000 a year ago. Adjusted EBITDA was $196,943,000 against $131,148,000 a year ago. Purchases of property and equipment were $20,091,000 against $46,892,000 a year ago. Non-GAAP net income attributable to the company was $111,125,000 or $0.54 per diluted share against $100,639,000 or $0.49 per diluted share a year ago. EBITDA was $188,504,000 against $158,063,000 a year ago. For the six months, the company reported total revenues of $10,300,287,000 against $6,637,147,000 a year ago. Operating income was $251,897,000 against $197,520,000 a year ago. The increases in both periods are mainly due to organic growth driven by increased claim volume added through new customer implementations, including the continued implementation of the Cigna contract, as well as additional claim volume related to the Restat acquisition. Additionally, revenues have increased in both periods as a result of increased specialty claim volume, which carries a higher revenue per claim rate compared to the Company's general book of business. Income before income taxes was $224,935,000 against $175,574,000 a year ago. Net income attributable to the company was $134,877,000 or $0.65 per basic and diluted share against $114,826,000 or $0.56 per basic and diluted share a year ago. Net cash provided by operating activities was $192,886,000 against $236,253,000 a year ago. Adjusted EBITDA was $376,875,000 against $255,503,000 a year ago. Purchases of property and equipment were $32,873,000 against $72,135,000 a year ago. Non-GAAP net income attributable to the company was $214,820,000 or $1.04 per diluted share against $187,834,000 or $0.91 per diluted share a year ago. EBITDA was $359,353,000 against $301,602,000 a year ago. The company updated its 2014 full year financial guidance. For the year, the company expected adjusted diluted EPS in the range of $2.12 to $2.22 from the prior range of $2.10 to $2.22. Revenues are now estimated to be $20.5 to $21.0 billion versus the previous guidance of $20 to $21 billion. And GAAP diluted EPS is now expected to be $1.40 to $1.50 from $1.38 to $1.50 previously. EBITDA is expected to be between $770 million and $800 million and effective tax rate is expected to be closer to 28% for the full year of 2014.

Catamaran Corporation to Report Q2, 2014 Results on Aug 01, 2014

Catamaran Corporation announced that they will report Q2, 2014 results at 6:00 AM, US Eastern Standard Time on Aug 01, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTRX:US $46.69 USD +0.06

CTRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioScrip Inc $7.82 USD +0.03
Cigna Corp $95.21 USD +1.12
Express Scripts Holding Co $74.60 USD +0.67
Walgreen Co $63.18 USD -0.55
WellPoint Inc $122.16 USD +1.94
View Industry Companies
 

Industry Analysis

CTRX

Industry Average

Valuation CTRX Industry Range
Price/Earnings 34.2x
Price/Sales 0.5x
Price/Book 1.9x
Price/Cash Flow 17.8x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CATAMARAN CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.